Share this article on:

Treatment with Peg-IFNα2a/ribavirin and low-dose NSAID for patients with chronic hepatitis C and rheumatoid syndrome

Lilea, Georgiana C.; Streba, Costin T.; Vere, Cristin C.; Rogoveanu, Ion

European Journal of Gastroenterology & Hepatology: January 2013 - Volume 25 - Issue 1 - p 65–68
doi: 10.1097/MEG.0b013e32835948c1
Original Articles: Hepatitis

Objective: To examine the safety and efficiency of using Peg-IFNα2a/ribavirin and low-dose NSAID therapy in patients with rheumatoid syndrome (RS) and chronic hepatitis C (CHC).

Methods: A group of 10 patients (group 1) known to have RS and established CHC undergoing Peg-IFNα2a/ribavirin and low-dose NSAID therapy was compared with a control group of 10 patients (group 2) also with CHC and associated RS, with no antiviral treatment. Their charts were reviewed for serological and clinical signs of rheumatic disease evolution while undergoing this type of treatment.

Results: At the end of a follow-up period of 12 months, patients receiving low-dose NSAID and Peg-IFNα2a/ribavirin therapy showed a sustained virusological response and also decreased levels of inflammation serological markers, with an improvement in the clinical rheumatic symptoms. In contrast, patients in group 2 showed no significant clinical modification in their rheumatic status.

Conclusion: Peg-IFNα2a/ribavirin and low-dose NSAID in patients with RS and CHC appear to be well tolerated and can be efficient for rheumatic manifestations. Further controlled studies are required to confirm the results.

Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Correspondence to Costin T. Streba, MD, PhD, Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, St. Petru Rares No 2-4, 200349 Craiova, Romania Tel: +40 722 389 906; fax: +40 251 310 287; e-mail:

Received February 27, 2012

Accepted August 13, 2012

© 2013 Lippincott Williams & Wilkins, Inc.